Blistering

FROM NIGHTCLUB TO ARENA: FRANK ZAPPA'S SHORT-LIVED 1980 LINEUP SHOWCASED ON LATEST VAULT TREASURE, 'ZAPPA '80: MUDD CLUB/MUNICH'

Retrieved on: 
Tuesday, January 10, 2023
Mudd Club, Love of My Life, The Meek Shall Inherit What's Left, Vinnie Colaiuta, Freak Out, U-matic, Dance, Cosmik Debris, Bernie, Nassau Coliseum, Tinsel Town Rebellion, Sheik Yerbouti, Pick Me, LOS, CD, AND, Blistering, Maestro, You Are What You Is, DoRo Productions, Joe's Garage, Rudi Dolezal, Nagra, Concord Music Group, Travers, Chunga's Revenge, You Can't Do That on Stage Anymore, Bass, Sony, Music, Michael H. Kenyon, Essay, Dancin' Fool, MUDD, Bobby Brown (song), Nite Owl, Drinking, Nightclub, Olympiahalle, Frank Zappa, Vault

Additionally, this is the first posthumous release of this distinct, brief lineup, as Logeman, who replaced drummer Vinnie Colaiuta, would end up leaving when Colaiuta returned to the band.

Key Points: 
  • Additionally, this is the first posthumous release of this distinct, brief lineup, as Logeman, who replaced drummer Vinnie Colaiuta, would end up leaving when Colaiuta returned to the band.
  • The Maestro was early to embrace the emerging technology and would importantly shift to it as a result of this recording.
  • Notably the band played an early rendition of "Pick Me, I'm Clean," which Zappa would release the following year on the double live album, Tinsel Town Rebellion.
  • Zappa '80: Mudd Club/Munich is an opportunity to experience Zappa and his terrific yet transitory 1980 band playing two fantastic concerts at two very different venues for the first time.

Hoosier Introduces New Sprint Car Dirt Tires

Retrieved on: 
Wednesday, December 21, 2022
Motor Sports, Sports, Automotive, General Automotive, Automotive Manufacturing, Manufacturing, Tires & Rubber, Off-Road Trucks & SUVs, Motorcycles, Blistering, H15, Longevity, Multimedia, Ageing, Hoosier, Tire manufacturing

Hoosier Racing Tire, the world’s largest manufacturer of racing tires, proudly announces the introduction of the newly designed rear drive tires for sprint car dirt racing in 2023.

Key Points: 
  • Hoosier Racing Tire, the world’s largest manufacturer of racing tires, proudly announces the introduction of the newly designed rear drive tires for sprint car dirt racing in 2023.
  • The new rear tires feature an updated symmetrical tread pattern design and profile allowing competitors to rotate tires to extend use and longevity compared to the current tires that have been in use for over 25 years.
  • “Along with the new designs, further consolidation of offerings will be implemented across various platforms of winged and non-winged sprint car racing.
  • “All January and February North America sprint car racing will remain on current tires based on current distributor and dealer inventory and allow teams to use current stock.

The Worldwide Decorative Coatings Industry is Expected to Reach $84.3 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 16, 2022
Chemicals, Plastics, Manufacturing, Blistering, Gold, Growth, Textile, Plastic, DIY, Food, Warchalking, Corrosion, COVID-19, Computer, F&B, Paint

Decorative coatings are used on the interior and exterior surfaces of different structures to enhance their aesthetics and protect them against moisture, ultraviolet (UV) radiations, corrosion, blistering, chalking, fading, and peeling.

Key Points: 
  • Decorative coatings are used on the interior and exterior surfaces of different structures to enhance their aesthetics and protect them against moisture, ultraviolet (UV) radiations, corrosion, blistering, chalking, fading, and peeling.
  • Moreover, leading players operating in the industry are focusing on product innovations to offer a better customer experience.
  • Apart from this, decorative coatings find extensive applications in mobile phones, computers, cameras, watches, door handles, eyewear, furniture, automotive parts, and bathroom equipment.
  • This, along with the rising demand for eco-friendly decorative coatings, is driving the market.

EQS-News: Medios AG presents growth strategy and announces medium-term targets at Capital Markets Day 2022

Retrieved on: 
Sunday, November 27, 2022
Growth, Pharmacy, EBITDA, Laboratory, United Kingdom, Blistering, Conference, RNA, Frankfurt Stock Exchange, Health, Patient, ISIN, Regulated market, GMP, Capital market, Good, Tax, SDAX, Medio, Depreciation, Fine chemical, Pharmaceutical industry

Expansion of the Patient-Specific Therapies segment by entering into the manufacture of personalized medicine (including RNA, gene and cell therapies)

Key Points: 
  • Expansion of the Patient-Specific Therapies segment by entering into the manufacture of personalized medicine (including RNA, gene and cell therapies)
    Berlin, November 24, 2022 Medios AG ("Medios"), the leading provider of Specialty Pharma Solutions in Germany, presents the Company's adapted growth strategy and the corresponding mid-term outlook at today's Capital Markets Day.
  • In addition to presenting its adapted strategy, Medios also announced mid-term goals for the first time at the Capital Markets Day.
  • As part of its adapted strategy, Medios AG also plans to exploit growth opportunities along the pharmaceutical value chain.
  • Medios AG is Germany's first listed Specialty Pharma company and is included in the SDAX selection index.

EQS-News: Medios AG significantly expands compounding capacity at Berlin site – manufacturing permit granted for new laboratory

Retrieved on: 
Friday, October 28, 2022
Growth, Goal, Laboratory, Conference, CEO, ISIN, Frankfurt Stock Exchange, Good, Pharmacy, SDAX, Health, Investment, Regulated market, GMP, Blistering, Medio, Fine chemical

-------------------

Key Points: 
  • Berlin, October 27, 2022 Medios AG ("Medios"), the leading provider of Specialty Pharma Solutions in Germany, yesterday received the manufacturing permit for the new GMP (Good Manufacturing Practice) clean room laboratory in Berlin from the responsible authority (Landesamt fr Gesundheit und Soziales; "LaGeSo").
  • For the new logistics center and the new laboratory site, Medios AG had rented a new building which covers a total area of approximately 4,500 square meters.
  • The new laboratory will start mid-November with the production of preparations for partner pharmacies of the Medios Group.
  • Matthias Gaertner, CEO of Medios AG: "Our new GMP laboratory at the Berlin site is one of the most modern, safe and effective laboratories in Germany.

Pureegg Introduced The Non-electric Moisture Removal Solution to the Market This Month

Retrieved on: 
Thursday, October 27, 2022
Intention, Glass, Efficiency, Water, Structural Damage, Family, Tablet, Research, Atmosphere, Blistering, Multimedia, Carbon, Health, Fluorine, Series, Environment, Absorption, Online shopping, Heating, ventilation, and air conditioning

FUZHOU, China, Oct. 27, 2022 /PRNewswire/ -- This month, Pureegg launched its first product, the energy-efficient Moisture Absorbers with hanging bag and box design.

Key Points: 
  • FUZHOU, China, Oct. 27, 2022 /PRNewswire/ -- This month, Pureegg launched its first product, the energy-efficient Moisture Absorbers with hanging bag and box design.
  • The Moisture Absorbers, Pureegg's primary contribution to environmental protection, are entirely in line with its values and mission.
  • The Pureegg team decided to experiment with non-electric Moisture Absorbers, which provide a more sustainable method of removing moisture.
  • The team highlighted the moisture removal efficiency and scents based on data gathered from over 500 people through user research and surveys.

Helsinn publishes new data evaluating chlormethine gel’s mode of action in Dermatology and Therapy

Retrieved on: 
Tuesday, October 18, 2022
Mycosis fungoides, Birth, Caregiver, Skin, Birth control, Smoking, Journal of Investigative Dermatology, Corporation, Blistering, Woman, Blister, Water, Dermis, Epidermis, Environment, Fertility, Fetus, Mycosis, Visual impairment, European Commission, Ulcer, Photophobia, Infertility, Permeation, Inflammation, Chlormethine, Red, Cancer, Medical Affairs Bureau, JAMA Dermatology, IB, Hypersensitivity, Itch, FDA, Dermatology, Female, Risk, Growth, Dermatitis, Research, Respect, Eye injury, Pain, Ageing, Royal commission, Nasal mucosa, Hyperpigmentation, Patient, Burns, Anaphylaxis, T-cell lymphoma, Swelling, CL, Toxicity, Adult, Safety, Heart, Pharmaceutical industry, Medical device, Medical imaging, Vaccine, Dentistry, EU

This article, Chlormethine Gel for the treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma: In Vitro Release and Permeation Testing, evaluated part of the mode of action of chlormethine (CL) gel once applied to the skin.

Key Points: 
  • This article, Chlormethine Gel for the treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma: In Vitro Release and Permeation Testing, evaluated part of the mode of action of chlormethine (CL) gel once applied to the skin.
  • In a preliminary, proof-of-concept, in vitro study, the release profile of 0.016% chlormethine gel was evaluated compared to an ointment-based formulation of CL.
  • Title: Chlormethine Gel for the treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma: In Vitro Release and Permeation Testing.
  • Understanding CL gels mode of action and how it permeates through the skin is extremely important for its use in clinical practice.

Artificial Intelligence Risk Incident Database launches to keep legal, financial professionals smart about evolving AI Risk and regulations.

Retrieved on: 
Friday, October 21, 2022
Adoption, News, Logic, PBC, Vocabulary, Finance, Risk, InterPlanetary File System, Gaps, Employment, Accenture, Software as a service, Existential risk from artificial general intelligence, Genocide, Intelligence, Ethics, Privacy, Professional corporation, Research, Instagram, Blistering, Technology, Automation, LOS, Mission control center, Software, Artificial intelligence marketing, Datastream, Industry, AI, Noise, United Kingdom, Artificial intelligence, Database, Death, Artifact, Engineering, Medical device, Responsibility

LOS ANGELES, Oct. 20, 2022 /PRNewswire/ -- The AI Responsibility Lab PBC, an enterprise SaaS company specializing in Responsible Artificial Intelligence (AI) transformation automation, released their newest product today: "Mission Control - AI Insights", a new module in their flagship Responsible AI transformation platform. AI Insights is the world's most complete AI Risk Incident intelligence and research platform. It helps legal, financial, and research teams stay informed on the accelerating landscapes of AI Risk, alleged harm incidents, and emerging global regulations. AI Insights delivers a combination of intelligent automation and advanced filtering that helps teams save hours of discovery and research time each week. AI Insights is available to try for free for 30 days at https://www.takecontrol.ai/insights.

Key Points: 
  • The AI Responsibility Lab releases "Mission Control - AI Insights" the world's most complete AI Risk Incident intelligence platform: www.takecontrol.ai/insights .
  • AI Insights is the world's most complete AI Risk Incident intelligence and research platform.
  • Legal teams are building cases where AI harm has been done, advising their clients on AI Risk reduction, and navigating the evolving global regulations around AI.
  • In response to professional teams' growing needs to navigate AI Risk, The AI Responsibility Lab developed the AI Insights platform.

Advanced Robotic Inspections Strengthen Critical Infrastructure Across European Market

Retrieved on: 
Thursday, October 13, 2022
Software, Robotics, Oil, Gas, Alternative Energy, Forest Products, Energy, Technology, Natural Resources, Other Manufacturing, Other Transport, Transport, Manufacturing, Time, Transport, Robotics, Efficiency, Corrosion, Pulp, Longevity, Siemens Energy, Blistering, Multimedia, Technology, CAPEX, Maintenance, HD, Laser, Inspection, Risk management, Machine shop

Gecko Robotics , a leader in using advanced robotics and enterprise software to help ensure the availability, reliability and sustainability of critical infrastructure, today announced a three-year collaboration with Siemens Energys European Field Service organization to market and perform advanced ultrasonic robotic inspections services across Europe.

Key Points: 
  • Gecko Robotics , a leader in using advanced robotics and enterprise software to help ensure the availability, reliability and sustainability of critical infrastructure, today announced a three-year collaboration with Siemens Energys European Field Service organization to market and perform advanced ultrasonic robotic inspections services across Europe.
  • View the full release here: https://www.businesswire.com/news/home/20221013005396/en/
    Gecko builds wall-climbing robots and enterprise software to protect the infrastructure of daily life.
  • (Photo: Business Wire)
    These advanced robotic inspections are poised to strengthen critical infrastructure and transform how installed equipment is inspected and maintained.
  • This results in optimized maintenance, greater uptime, informed CAPEX investment, significant cost savings, lower environmental footprints and fewer workplace injuries.

Accord Healthcare Adds Pemetrexed Injection to Generic Chemotherapy Drug Portfolio

Retrieved on: 
Tuesday, September 13, 2022
Intas Biopharmaceuticals, Malignancy, Incidence, Mesothelioma, Ageing, Pemetrexed, Chest pain, Blistering, FDA, Solution, NSCLC, Vomiting, Population, MPM, Product, Lung cancer, Patient, Accord, Cancer, Technology, Heart, Research, Nausea, Fatigue, Chemotherapy, Pharmaceutical industry

DURHAM, N.C., Sept. 13, 2022 /PRNewswire/ -- Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Pemetrexed Injection (Solution) to its line of chemotherapy drugs. The new drug is formulated as a single-dose vial in 25-mg/ml concentrate for solution for infusion.

Key Points: 
  • DURHAM, N.C., Sept. 13, 2022 /PRNewswire/ --Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Pemetrexed Injection (Solution) to its line of chemotherapy drugs.
  • The new drug is formulated as a single-dose vial in 25-mg/ml concentrate for solution for infusion.
  • Accord Healthcare, a wholly owned subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company.
  • Accord Healthcare combines its advanced manufacturing technology with in-house research to produce highly complex, affordable, and essential medicines.